The global ornithine transcarbamylase (OTC) deficiency treatment market was valued at US$ 600 Mn in 2021. It is projected to expand at a CAGR of 4% from 2022 to 2030.
The global ornithine transcarbamylase (OTC) deficiency treatment market was valued at US$ 600 Mn in 2021. It is projected to expand at a CAGR of 4% from 2022 to 2030.
Innovations in IV Medications for Life-threatening OTC Deficiency Surface amidst COVID-19 Outbreak
Since OTC deficiency is a rare X-linked genetic disorder, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are under pressure to increase the availability of drugs amidst the COVID-19 (coronavirus) outbreak. Messenger RNA drug developer Arcturus Therapeutics has not only received the FDA’s (Food & Drug Association) approval for clinical trials of ARCT-810, an investigational treatment for OTC deficiency, but is also testing its coronavirus vaccine candidate. Thus, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are tapping revenue opportunities by innovating in COVID-19 vaccines.
Download Sample @ https://qyresearchmedical.com/sample/111619
OTC deficiency is a life-threatening disorder, which needs extra care and attention during the COVID-19 pandemic. Companies are collaborating with retail and hospital pharmacies to avoid supply shocks for OTC deficiency medications, as most individuals are opting for remote healthcare diagnosis. They are innovating in intravenous (IV) medications since no FDA-approved drugs exist for the disorder.
Gene Therapy Helps Minimize Neurological Deficits and Liver Damage in Patients
Gene therapy holds promising potentials in ornithine transcarbamylase (OTC) deficiency treatment. The Boston Children’s Hospital is creating awareness about gene therapy, since OTC deficiency is a genetic condition caused due to the mutation of the OTC gene. By providing a healthy copy of the OTC gene through gene therapy, doctors aim to reduce incidence of neurological deficits and liver damage. Liver transplantation is another solution for ornithine transcarbamylase deficiency treatment.
Companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing their production capabilities to manufacture BUPHENYL® (sodium phenylbutyrate) tablets and powder for oral administration. Since urea cycle disorders are commonly associated with the OTC deficiency, manufacturers in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing the availability of BUPHENYL® to minimize adverse events in patients. BUPHENYL® is being used as an adjunctive therapy for chronic management of OTC deficiency.
Safety Information Enables Management of Extremely High Levels of Ammonia in Blood
Ravicti has become the gold standard for the treatment of the OTC deficiency. This oral liquid is being increasingly used for long-term management of high blood levels containing ammonia that commonly lead to urea cycle disorders (UCDs). Healthcare practitioners are recommending low-protein diet and dietary supplements to OTC deficiency patients. However, Ravicti has limitations for the treatment of extremely high levels of ammonia in the blood, especially in patients with UCD. This explains why the market is estimated to register a modest CAGR of ~4% during the forecast period. Hence, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing awareness about the safety of Ravicti to avoid serious side effects in patients.
OTC deficiency patients with kidney and liver problems need to seek doctor’s consultation before consuming Ravicti. Clinicians are providing special care to pregnant women and women who are breastfeeding to avoid any adverse events in infants.
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111619/2900
Ammonul IV Holds Promising Potentials for Lowering Ammonia Levels in OTC Deficiency Patients
The FDA prescribed information is being used by medical practitioners to administer the doses of Ammonul in OTC deficiency patients. Genetics and metabolic experts are recommending hemodialysis as an effective solution to reduce plasma ammonia in OTC deficiency patients. As such, Ammonul is being extensively taken via intravenous administration to reduce the severity of UCDs. Ammonul IV helps in removing glycine and glutamate from plasma, thereby reducing contribution to ammonia formation. Thus, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing their R&D capabilities to develop improved formulations of Ammonul IV.
Since the management and diagnosis of UCD is complex, pathologists, nephrologists, and geneticists are stepping in to lower ammonia levels in the blood of OTC deficiency patients.
Nitrogen Scavenger Therapy Ensures Long-term UCD Management
The ornithine transcarbamylase (OTC) deficiency treatment market is projected to reach ~US$ 900 Mn by the end of 2030. However, limited consensus regarding long-term management approaches for OTC deficiency is potentially inhibiting market growth. Hence, pharmaceutical companies are introducing efficacious dietary supplements to keep ammonia levels in the blood under control. On the other hand, nitrogen scavenger therapy is being highly publicized to ensure long-term UCD management and to minimize the nitrogen load.
Companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing awareness about a multidisciplinary approach for long-term UCD management. Since the male population is at a higher risk of being susceptible to the OTC deficiency, biochemical geneticists, dieticians and neuropsychologists are collaborating to introduce guidelines associated with chronic ammonia targets.
Dieticians Deliver Complex Calculations for Intake of Protein and Dietary Supplements
It has been found that a dietician’s consultation helps to improve clinical outcomes in OTC deficiency patients. Along with dietary supplements, nutritionists are recommending low-protein diets to improve the quality of life for OTC deficiency individuals. Patients that are adherent to the UCD therapy are also warranted for genetic testing to ensure successful management of OTC deficiency. Dieticians are playing an instrumental role in complex calculations related to the intake of protein and dietary supplements, which depends on different variables such as age-related growth rate, physical activity, and residual urea cycle function.
Providing the right amount of protein is necessary for efficient management of the OTC deficiency. Hence, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are suggesting routine diagnosis of the rare disorder in order to increase clinical numbers. IV and oral drugs are being routinely used for long-term management of UCD in OTC deficiency patients.
Analysts’ Viewpoint
Since UCD associated with OTC deficiency can be potentially life threating for patients amidst the COVID-19 pandemic, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are boosting their production capacities to increase the availability of IV and oral drugs. Gene therapy and nitrogen scavenger therapy are gaining popularity for long-term management of ammonia in blood streams. Since there is a lack of FDA-approved drugs for the OTC deficiency, companies in the ornithine transcarbamylase (OTC) deficiency treatment market should increase their R&D capabilities to innovate in IV medications. Companies should innovate in dietary supplements, since a close check on daily intake of protein and supplements helps to improve patient quality of life.
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Overview
Ornithine transcarbamylase deficiency, a highly common urea cycle disorder and rare X-linked genetic disorder, is characterized by partial or a complete lack of enzyme ornithine transcarbamylase (OTC)
OTC is one of six enzymes that play a role in breakdown and removal of nitrogen in the body, a process known as the urea cycle
OTC deficiency is a genetic disorder characterized by a complete or partial lack of the enzyme ornithine transcarbamylase (OTC). It is an abnormal gene on the X chromosome and manifests mostly in males.
Both males and females may develop symptoms of OTC deficiency during childhood. Females who have a defective gene present on one of their X chromosomes are carriers for the disorder.
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Drivers
Rising prevalence of OTC deficiency and development of new therapies for the treatment of OTC deficiency are major factors boosting the global ornithine transcarbamylase (OTC) deficiency treatment market
For instance, according to Orphanet, the estimated prevalence of ornithine transcarbamylase deficiency ranges between 1/56,500 and 1/113,000 live births across the world
Favorable reimbursement scenario and patient assistance programs provided by various international as well as regional organizations are also major drivers of the global Ornithine Transcarbamylase (OTC) deficiency treatment market
Patient compliance is affected due to bitter taste and foul odor of products. Hence, research and development is being carried out to develop new formulations of this drug in order to overcome such serious issues.
Consequently, formulation modification for better patient compliance also propels the global ornithine transcarbamylase (OTC) deficiency treatment market
Market Segmentation: Ornithine Transcarbamylase (OTC) Deficiency Treatment Market
In terms of product, the global ornithine transcarbamylase (OTC) deficiency treatment market has been divided into Buphenyl, Ravicti, Ammonul, dietary supplements, and others
Based on route of administration, the global ornithine transcarbamylase (OTC) deficiency treatment market has been bifurcated into oral and intravenous
In terms of distribution channel, the global ornithine transcarbamylase (OTC) deficiency treatment market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies
Each of the ornithine transcarbamylase (OTC) deficiency treatment market segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights
The ornithine transcarbamylase (OTC) deficiency treatment market report provides current and future revenues (US$ Mn) for each of the segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030 along with market size estimations.
Regional Overview: Ornithine Transcarbamylase (OTC) Deficiency Treatment Market
In terms of region, the global ornithine transcarbamylase (OTC) deficiency treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
North America dominated the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019, and the trend is projected to continue during the forecast period
The current and future sizes of the ornithine transcarbamylase (OTC) deficiency treatment market, in terms of value (US$ Mn), of regional markets and their major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
The study also offers a list of recommendations, highlights, and useful insights of the market, which would help new companies willing to enter the market and existing companies to increase market shares and help in the decision-making process
Major Players
The ornithine transcarbamylase (OTC) deficiency treatment market report concludes with the company profiles section that includes key information about the major players in the market
Key players analyzed in the ornithine transcarbamylase (OTC) deficiency treatment market report are –
- Abbott
- Nutricia (Danone Group)
- Mead Johnson (Reckitt Benckiser)
- Horizon Therapeutics plc
- Nestlé
- Bausch Health Companies, Inc.
- Ultragenyx Pharmaceutical Inc.
- Arcturus Therapeutics, Inc.
- Acer Therapeutics
Each of these players has been profiled in the global ornithine transcarbamylase (OTC) deficiency treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Key Questions Answered in Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Report
- What is the sales/revenue generated by each product, route of administration, and distribution channel segment of the global ornithine transcarbamylase (OTC) deficiency treatment market across all regions during the forecast period?
- What are the opportunities in the global ornithine transcarbamylase (OTC) deficiency treatment market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which region is likely to expand at the fastest CAGR during the forecast period?
- Which ornithine transcarbamylase (OTC) deficiency treatment segments are expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
- What is the market share or position of different companies operating in the global market in 2019?
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market – Segmentation
Product
- Buphenyl
- Ravicti
- Ammonul
- Dietary Supplements
- Others
Route of Administration
- Oral
- Intravenous
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111619/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/